ArticleFrontiers in medicine2026
A clinical study on the application of new inflammatory markers SII, SIRI, AISI, and MII in the identification of severe acute pancreatitis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pancreatitis (AP) is an inflammatory disease characterized by sudden onset. The mortality rate increases significantly if it progresses to severe acute pancreatitis (SAP). Current clinical scoring systems are complex. Consequently, there is a clinical need for novel inflammatory markers that are inexpensive, fast, accurate, and easy to use. Herein, we aimed to evaluate the clinical value of the following novel inflammatory markers for predicting SAP at admission and assessing AP severity at 48 h after admission: the systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), aggregate index of systemic inflammation (AISI), multi-inflammatory index-I (MII-1), multi-inflammatory index-II (MII-2), multi-inflammatory index-III (MII-3). Methods: A retrospective analysis was conducted on 374 patients with AP hospitalized at Shijiazhuang People's Hospital, including 58 cases in the severe group and 316 cases in the non-severe group. Receiver operating characteristic curve analysis and pairwise DeLong tests were used to compare marker performance. Separate multivariable logistic regression models were constructed for each inflammatory marker with adjustment for clinical factors. Internal validation of the adjusted models was performed using 2,000 bootstrap resamples. Results: The SII, SIRI, AISI, MII-1, MII-2, and MII-3 emerged as statistically significant ( Conclusion: MII-1, MII-2, and MII-3 showed moderate-to-good discriminatory performance for assessing AP severity at 48 h after admission, particularly MII-1, and their associations with SAP remained significant after adjustment for clinical factors. These findings should be considered exploratory and hypothesis-generating, and further studies are needed to validate the potential value of MII indices in AP severity assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.